RAPPRapport Therapeutics Inc

Rapport Therapeutics, Inc. (RAPP) delivered earnings and revenue surprises of +24.66% and 0.00%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Rapport Therapeutics (NASDAQ:RAPP) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at...

Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) has been assigned a consensus rating of "Buy" from the ten brokerages that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, seven have issued a buy rating and two have issued a s...

Key PointsA major owner of Rapport Therapeutics reported selling 426,005 shares for a total value of approximately $17.18 million on April 17, 2026...

BTIG Research restated a "buy" rating and issued a $53.00 target price on shares of Rapport Therapeutics in a research note on Wednesday...

Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) insider Krishnaswamy Yeleswaram sold 20,225 shares of Rapport Therapeutics stock in a transaction dated Friday, April 17th. The shares were sold at an average price of $39.99, for a total value of $808,797.75. Following the transaction, the...

Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) major shareholder Rock Ventures L.P. Third sold 426,005 shares of Rapport Therapeutics stock in a transaction dated Friday, April 17th. The...

Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) insider Krishnaswamy Yeleswaram sold 20,225 shares of the company's stock in a transaction on Friday, April 17th. The stock was sold at an average price of $39.99, for a total transaction of $808,797.75. Following the completion of the...

Rapport Therapeutics (NASDAQ:RAPP) Stock Price Down 4.2% - Time to Sell...